G

    Gossamer Bio Inc (GOSS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.17
    -0.00 (-0.06%)

    Market Cap: $83.10M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    45%(14/31)
    Avg Surprise
    -65.21%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.05
    Range$-0.09 - $0.01
    5 analysts
    EPS Revisions
    1
    0
    7d
    2
    0
    30d
    EPS Estimate Drift
    90d ago$-0.09-82.7%
    60d ago$-0.08-68.5%
    30d ago$-0.07-50.8%
    7d ago$-0.05+2.9%
    Current$-0.05
    Revenue Consensus
    $11M
    Range$0 - $41M
    6 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.16
    Range$0.12 - $0.20
    2 analysts
    Revenue Consensus
    $17M
    Range$7M - $42M
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.16---
    Sep 26EST
    		-$-0.05---
    Jun 26
    Reported Aug 4
    		$-0.20$-0.10-100.00%Miss-17.6%
    Mar 26
    Reported May 18
    		$-0.20$-0.17-17.65%Miss-25.0%
    Dec 25
    Reported Mar 17
    		$-0.21$-0.18-13.51%Miss-40.0%
    Sep 25
    Reported Nov 5
    		$-0.21$-0.19-10.53%Miss-50.0%
    Jun 25
    Reported Aug 5
    		$-0.17$-0.18+5.56%Beat-177.3%
    Mar 25
    Reported May 15
    		$-0.16$-0.18+11.11%Beat+15.8%
    Dec 24
    Reported Mar 13
    		$-0.15$-0.17+10.71%Beat+28.6%
    Sep 24
    Reported Nov 7
    		$-0.14$-0.14+0.00%Beat+33.3%
    Jun 24
    Reported Aug 12
    		$0.22$0.27-18.52%Miss+148.9%
    Mar 24
    Reported May 7
    		$-0.19$-0.19+0.00%Beat+63.5%
    Dec 23
    Reported Mar 5
    		$-0.21$-0.21+0.00%Beat+64.4%
    Sep 23
    Reported Nov 9
    		$-0.21$-0.27+22.22%Beat+67.7%
    Jun 23
    Reported Aug 8
    		$-0.45$-0.50+10.00%Beat+39.2%
    Mar 23
    Reported May 9
    		$-0.52$-0.54+3.70%Beat+31.6%
    Dec 22
    Reported Mar 17
    		$-0.59$-0.62+4.84%Beat+20.3%
    Sep 22
    Reported Nov 3
    		$-0.65$-0.66+1.52%Beat+18.8%
    Jun 22
    Reported Aug 9
    		$-0.74$-0.69-7.25%Miss+7.5%
    Mar 22
    Reported May 10
    		$-0.76$-0.76+0.00%Beat+2.6%
    Dec 21
    Reported Mar 3
    		$-0.74$-0.74+0.00%Beat+15.9%
    Sep 21
    Reported Nov 8
    		$-0.80$-0.77-3.90%Miss+0.0%
    Jun 21
    Reported Aug 9
    		$-0.80$-0.76-5.26%Miss+20.0%
    Mar 21
    Reported May 6
    		$-0.78$-0.74-5.41%Miss+10.3%
    Dec 20
    Reported Feb 25
    		$-0.88$-0.79-11.39%Miss+1.1%
    Sep 20
    Reported Nov 10
    		$-0.80$-0.85+5.88%Beat+0.0%
    Jun 20
    Reported Aug 11
    		$-1.00$-0.86-16.28%Miss-35.1%
    Mar 20
    Reported May 12
    		$-0.87$-0.75-16.00%Miss+3.3%
    Dec 19
    Reported Mar 24
    		$-0.89$-0.86-3.49%Miss+95.1%
    Sep 19
    Reported Nov 12
    		$-0.80$-0.68-17.65%Miss+14.0%
    Jun 19
    Reported Aug 8
    		$-0.74$-0.43-72.09%Miss-
    Mar 19
    Reported May 14
    		$-0.90$-0.58-55.17%Miss-
    Dec 18
    Reported Feb 12
    		$-18.23$-1.00-1723.00%Miss-
    Sep 18
    Reported Oct 11
    		$-0.93$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.21EV/EBITDA-0.39x
    Price/FCF-0.33xFCF Yield-298.93%
    Profitability
    Profit Margin-235.00%Operating Margin-282.20%
    ROE-783.00%ROIC218.30%
    Financial Health
    Debt/Equity-0.38xInterest Coverage4.86x
    Current Ratio0.53xQuick Ratio0.53x
    Trading Statistics
    Beta2.01Avg Volume21.53M
    52-Week High$3.8752-Week Low$0.11

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.17
    SMA 20$0.17
    SMA 50$0.17
    SMA 200$1.16
    EMA 10$0.17
    EMA 20$0.17
    EMA 50$0.19
    EMA 200$0.80

    MACD

    Line: -0.00Signal: -0.00Hist: 0.00

    ADX

    ADX: 21.7+DI: 28.0-DI: 14.1

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down64.0
    PSAR$0.20

    Bollinger Bands

    Upper Band$0.20
    Lower Band$0.14
    %B Position3520%(Upper)
    Band Width0.51

    RSI (14-Day)

    Neutral
    49.8

    Momentum Oscillators

    Stoch %K42.2
    Stoch %D48.4
    Williams %R-57.9
    ROC (10d)21.4%
    Momentum0.03
    CCI (20d)19.9
    MFI (14d)34.8

    Volatility Measures

    ATR (14d)$0.02(12.4%)
    StdDev (20d)0.01
    Hist Vol116.0%(High)

    Volume Flow

    VWAP$0.17
    OBV-215.9M
    AD Line-88.2M
    CMF (20d)-0.053

    Volume Metrics

    Avg Vol (20d)21.7M
    Vol Ratio0.5x(Low)
    VWMA (20d)$0.17

    Pivot Points

    R3$0.18
    R2$0.18
    R1$0.17
    Pivot Point$0.17
    S1$0.17
    S2$0.16
    S3$0.16

    Advanced Oscillators

    TSI-0.25
    Ultimate Osc50.2
    KST-11.53

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$9.24M$16.95M$13.80M$13.29M$11.49M$9.89M$9.38M$9.48M$95.84M$0$6.78M$0
    Cost of Revenue$0$0$227,000$0$0$0$1.07M$0$0$0$1.01M$0
    Gross Profit$9.24M$16.95M$13.80M$13.29M$11.49M$9.89M$9.38M$9.48M$95.84M$0$5.78M$0
    Operating Expenses$35.31M$61.82M$59.84M$62.41M$50.25M$46.70M$45.51M$43.40M$43.76M$41.96M$49.04M$40.49M
    R&D$26.41M$43.08M$48.93M$53.02M$41.58M$38.04M$36.11M$34.90M$35.09M$32.39M$40.00M$31.20M
    SG&A$8.90M$18.75M$10.90M$9.39M$8.68M$8.66M$9.39M$8.50M$8.67M$9.57M$9.06M$9.29M
    Operating Income$-26,074,000$-44,866,000$-46,039,000$-49,114,000$-38,765,000$-36,810,000$-36,128,000$-33,919,000$52.09M$-41,959,000$-49,027,000$-40,490,000
    Interest Income$268,000$354,000$447,000$687,000$542,000$294,000$-744,000$430,000$1.75M$344,000$310,000$405,000
    Interest Expense$-41,141,000$2.75M$2.75M$2.75M$2.74M$2.75M$2.74M$2.73M$2.92M$3.13M$3.24M$3.34M
    Income Before Tax$16.90M$-46,664,000$-47,326,000$-48,221,000$-38,273,000$-36,638,000$-35,439,000$-31,935,000$53.67M$-41,928,000$-48,148,000$-40,008,000
    Income Tax Expense$0$0$0$0$0$0$0$-1,132,000$4.43M$0$0$0
    Net Income$16.90M$-46,664,000$-47,238,000$-48,221,000$-38,273,000$-36,638,000$-33,029,000$-30,803,000$49.23M$-41,928,000$-48,148,000$-40,008,000
    EBITDA$-19,694,000$-44,436,000$-45,626,000$-47,277,000$-37,557,000$-36,270,000$-34,008,000$-31,957,000$53.15M$-40,911,000$-47,487,000$-38,491,000
    EBIT$-24,509,000$-44,263,000$-45,022,000$-46,160,000$-36,071,000$-34,186,000$-31,957,000$-29,631,000$54.83M$-39,143,000$-45,219,000$-37,070,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about GOSS

    News

    Gossamer Bio Amends Charter for New Preferred Financing

    Gossamer Bio (GOSS) has amended its certificate of incorporation to establish Series A-1 Convertible Preferred Stock, a crucial step for its previously announced private placement. This charter change formalizes investor rights and enhances the company's capital flexibility and financial base. The move aims to strengthen its funding capacity and aligns with the analyst rating of "Buy" with a $2.00 price target, though TipRanks' AI Analyst, Spark, rates GOSS as "Neutral" due to weak financial performance.

    TipRanks•8/27/26•
    Neutral

    H.C. Wainwright reiterates Gossamer Bio stock rating on NDA progress

    H.C. Wainwright has reiterated a Buy rating and a $2.00 price target for Gossamer Bio Inc. (NASDAQ:GOSS) shares, following the company's progress towards submitting a New Drug Application (NDA) for seralutinib in pulmonary arterial hypertension in September. The submission is supported by positive Phase 3 and Phase 2 trial data, with the FDA characterizing the statistical significance and treatment effect as review rather than filing issues. Gossamer Bio has also reacquired worldwide rights to seralutinib and completed a convertible note exchange to reduce debt, alongside a private placement to secure further funding.

    Investing.com•8/27/26•
    Somewhat-Bullish

    $Gossamer Bio (GOSS.US)$ they cant recover. 👩‍🚀🚀

    A Moomoo community user, Smokey The Bear, posted a brief comment regarding Gossamer Bio (GOSS.US), stating "they cant recover." The comment includes emojis suggesting a negative outlook for the stock. This post is shared within the Moomoo community for educational purposes.

    Moomoo•8/25/26•
    Bearish

    Gossamer Bio (NASDAQ: GOSS) has 6% of its stock under D. E. Shaw’s reported influence

    D. E. Shaw group has reported a 6% stake in Gossamer Bio (NASDAQ: GOSS) through an Amendment No. 3 to a Schedule 13D filing. This includes holdings by D. E. Shaw Valence Portfolios, L.L.C. (5.7%) and D. E. Shaw Cogence Portfolios, L.L.C. (0.3%), totaling 29,128,194 common shares with shared voting and dispositive power. The filing also details the control relationships of various D. E. Shaw entities and David E. Shaw, who disclaims direct beneficial ownership.

    Stock Titan•8/25/26•
    Neutral

    Gossamer Bio announces $250m in funding to advance seralutinib

    Gossamer Bio has secured up to $250 million in funding, with $150 million committed, to support the development and potential FDA approval of its drug seralutinib. The drug is intended to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The financing structure aligns capital availability with key regulatory milestones, including an upcoming NDA submission by September 2026.

    Yahoo Finance•8/24/26•
    Bullish

    Frequently Asked Questions About GOSS

    Does GOSS pay dividends?
    Gossamer Bio Inc (GOSS) does not currently pay a regular dividend.
    What is GOSS's market cap?
    Gossamer Bio Inc (GOSS) has a market capitalization of $83.10M with a current stock price of $0.17.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In